Call for Abstract

7th International Conference and Exhibition on Cell and Gene Therapy, will be organized around the theme “Exploring the novel research and innovations in Cell & gene therapy”

Cell Therapy 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Cell Therapy 2018

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Cell therapy is defined as the therapy in which cellular material is injected into a patient in order to recover the healthy tissue. Cell therapy is targeted at many clinical indications in multiple organs by means of several modes of cell delivery. Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Stem cells are a class of undifferentiated cells which are able to differentiate into required or specialized cell types. Adult or somatic stem cells exist throughout the body after embryonic development and are found available inside the different types of tissue. The stem cell methodology includes the phases of Stem cell or progenitor cell engraftment, differentiation followed by long term replacement of damaged tissue.

  • Track 1-1Cell Therapies
  • Track 1-2Somatic Cell Nuclear Transfer (SCNT)
  • Track 1-3Embryonic Stem Cells (ES cells)
  • Track 1-4Hematopoietic Stem Cells Transplant(HSCT)
  • Track 1-5Gene Therapy
  • Track 1-6Antisense Technology

A stem-cell line is a group of undifferentiated stem cells which is cultured invitro and can be propagated indefinitely. While stem cells can propagate indefinitely in culture due to their inherent cellular properties, immortalized cells would not normally divide indefinitely but have gained this ability to sustain due to mutation. The Immortalized cell lines can be generated from cells by means of isolating cells from tumors or induce mutations to make the cells immortal. An immortalised cell line is a population of multicellular organism cells which has not proliferates indefinitely. Due to mutation, the cells evaded normal cellular senescence and instead undergoing continuous cell division. A key factor in reducing the production costs of biopharmaceuticals is the development of cell lines which in turn produce a high yield of product

  • Track 2-1Cell Culture
  • Track 2-2Immortalized Cell Lines and its Types
  • Track 2-3Human Cell Lines
  • Track 2-4Plant Cell Lines
  • Track 2-5Primate Cell Lines
  • Track 2-6Cancer Cell Line

Classical methods of gene therapy include transfection. It became inefficient and limited mainly due to delivery of gene into actively proliferating cells invitro. Gene therapy utilizes the delivery of DNA into cells by means of vectors such as biological nanoparticles or viral vectors and non-viral methods. The Several kinds of viruses vectors used in gene therapy are retrovirus, adenovirus, adeno-associated virus and herpes simplex virus. While other recombinant viral vector systems have been developed, retroviral vectors remain the most popular vector system for gene therapy protocols and widest application due to their historical significance as the first vectors developed for efficient gene therapy application and the infancy of the field of gene therapy

  • Track 3-1Viral Vector in Gene Therapy
  • Track 3-2Retroviral and Other Viral Vector
  • Track 3-3Non -Viral Vectors in Gene Therapy
  • Track 3-4Calcium Phosphate Transfection
  • Track 3-5Electroporation
  • Track 3-6Targeted Vector Systems
  • Track 3-7Transductional Targeting
  • Track 3-8Fusion Protein Targeting
  • Track 3-9Targeting Cell Surface Molecules

Gene therapy is used to treat inherited Muscular disorder, cardiovascular disorder, HIV, cancer etc. In stem cell transplants, stem cells replace cells damaged by chemotherapy or disease or as a way for the donor's immune system to provoke immunity against some types of cancer and blood-related diseases, such as leukemia. Cellular Therapy is internationally recognized for its novel approaches in treating blood related disorders like leukemia, lymphoma, myeloma, and other life threatening diseases. The stem cell transplantation of hematopoietic stem cells (HSCS) in which the allogeneic hematopoietic stem cells are harvested from healthy donors of same species and autologous stem cell from the patient itself. Both therapies use high dosage cytotoxic medication in order to induce higher remission rates against malignant diseases. Autologous cell HSCT preferably used in relapsed malignant high-grade lymphoma and Allogeneic HSCT preferred for therapeutic effect against acute leukemia with unfavourable prognosis in a high percentage of patients. The Recent developments based on the expansion of the donor pool for allogeneic stem cells in order to reduce dosage as well as chemotherapeutic toxicity of allogeneic transplantation with sustainable anti-leukemia efficacy.

  • Track 4-1Neurological Disorder
  • Track 4-2Blindness Vision Impairment
  • Track 4-3Wound Healing
  • Track 4-4Cancer
  • Track 4-5HIV
  • Track 4-6Cardiovascular Disorder
  • Track 4-7Inherited Muscular Disorder
  • Track 4-8Orthopedic Repair

Regenerative medicine is the branch of translational research deals with the process of replacing, engineering or regenerating human cells, tissues or organs in order to restore or establish normal functionality of cell. Regenerative medicine is the combination of   tissue engineering and molecular biology. Cell therapy mediate cell repair via five primary mechanism:  providing an anti-inflammatory effect, homing to damaged tissues and recruiting other cells, such as endothelial progenitor cells and therapy for necessary tissue growth, supporting tissue remodeling over scar formation, inhibiting apoptosis programmable cell death, and differentiating tissues into bone, cartilage, tendon, and ligament tissue.

  • Track 5-1Immunotherapy
  • Track 5-2Biomaterial Mediated Gene Therapy
  • Track 5-3Extracellular Matrix in Reconstructive Surgery
  • Track 5-4Endothelial Progenitor Cells
  • Track 5-5Tissue Remodelling

Epigenetics refers to changes in a chromosome which has influence on gene activity and expression. It is also used to describe any heritable phenotypic change that doesn't derive from a modification of the genome, such as prions. Epigenetics is the mechanism for storing and perpetuating or continuing indefinitely a “memory” at the cellular level. The basic molecular epigenetic mechanisms that are widely studied at present – regulation of chromatin structure of cell through histone post-translational modifications and covalent modification of DNA principally through the method of DNA methylation. Chromatin is a dynamic structure that integrates potentially hundreds of signals from the cell surface and has effects of coordinated and appropriate transcriptional response in cell. It is increasingly clear that epigenetic marking of chromatin and DNA itself is an important component of the signal integration of entire function that is performed by the genome. Moreover, the changes in the epigenetic state of chromatin in cell can have lasting effects on behavioral changes.

  • Track 6-1Molecular Bridge
  • Track 6-2Neuroepigenetics
  • Track 6-3Histone Post-Translational Modification
  • Track 6-4DNA Methylation
  • Track 6-5Prion Based Epigenetic Inheritance
  • Track 6-6Cellular Storage Information

Clinical trials of CGT products often varying from the clinical trials design for other types of pharmaceutical products .This differences in trial design are necessitated by the distinctive features of these products. The clinical trials also reflect previous clinical experience and evidence of medicine. Early experiences with CGT products indicate that some CGT products may pose substantial risks to subjects due to effect at cellular and genetic level. The design of early-phase clinical trials of Cell and Gene Therapy products often involves the following consideration of clinical safety issues, preclinical issues, and chemistry, manufacturing and controls (CMC) issues that are encountered.

  • Track 7-1Evidence on Medicine
  • Track 7-2Ethical Issues
  • Track 7-3Clinical Risks
  • Track 7-4Preclinical Issues
  • Track 7-5Regulatory and Safety Aspects
  • Track 7-6Chemistry,Manufacturing and Controls (CMC )Information

The extract derived from the plant cells culture technology is being harnessed and utilized as an active ingredient in anti-aging skincare products. In recent years, researchers have identified naturally occurring botanicals with substantial antioxidant activity proven to protect skin stem cells from UV-induced oxidative stress, inhibit inflammation, neutralize free radicals and reverse the effects of photoaging by means of antioxidant activity. Consequently, cosmeceutical products containing plant stem cells derived extracts have the ability to promote healthy cell proliferation and protect against UV-induced dermatological cellular damage in humans. In contrast to epidermal stem cells, plant stem cells are totipotent stem cells that they are capable of regenerating an entirely new, whole plant. Through innovative plant stem cell technologies, scientists are able to extract tissue from botanicals and regenerate stem cells can be harnessed for use in humans. The use of stem cells derived from botanicals plant, rather than human stem cells, avoids the controversy surrounding the source or methods of extraction of human stem cells while still harnessing the potential of these intriguing cells and its effect in anti-photo aging.

  • Track 8-1Plant Stem Cells as Anti Oxidant
  • Track 8-2Anti Photoaging Effect
  • Track 8-3Strategies for Engineered Scenescence
  • Track 8-4Hematopoietic Stem Cell Aging
  • Track 8-5Hair Follicle Stem Cell Aging

Tissue engineering or bioengineering is the combinational usage of cells, engineering, materials methods, suitable biochemical and physicochemical factors in order to improve or replace the infected biological tissues. The field includes the development  of  materials, devices,  techniques to detect and  differentiate disease states ,the treatment response, aid tissue healing, precisely deliver treatments to tissues or cells, signal early changes in health status, and provide implantable bio artificial replacement organs for recover or establish of healthy tissue .Techniques developed here identify and detect biomarkers of disease sub-types, progression, and treatment response, from tissue imaging to genetic testing and single cell analysis, that aid the more rapid development of new treatments and guide their clinical applications in treating the disorder. It includes the usage of computational modeling, bioinformatics, and quantitative pharmacology to integrate data from diverse experimental and clinical sources to discover new drugs and specific drug targets, as well as to design more efficient and informative preclinical, clinical safety and efficacy studies.

  • Track 9-1Biomarkers
  • Track 9-2Metabolic Imaging Technology
  • Track 9-3Computational Modelling
  • Track 9-4Bio Informatics
  • Track 9-5 Quantitative Pharmacology
  • Track 9-6Gene Therapy for Bone Engineering
  • Track 9-7Talen Technology

Diseases can be treated using viruses as vector to deliver genes in gene therapy. Viruses as gene vector, however, can themselves cause problems in that they may initiate inflammation and the genes may be expressed at too high a level or for too long period of exposure. The goal of Nano technology in gene therapy is delivery of therapeutic genes without a virus, using nanoparticles as non-viral vector to deliver the genes.  The particles can be made with multiple layers so the outer layer with covering of peptide that can target the particles to cells of interest at specific site. The emergent Nanotechnology in gene therapy is used to develop unique approaches in treating the retinopathies and the development of micro and nano dimensional artificial antigen presenting cells (aAPCs) for cancer immunotherapy. These aAPCs mimic the natural signals in immunity that killer T-cells receive when there is an invader (bacteria, virus, cancer cell, etc.) in the body.

  • Track 10-1Nano Technology in Gene Therapy
  • Track 10-2Non Viral Vector
  • Track 10-3Immune System Modulation
  • Track 10-4DNA Nanotechnology
  • Track 10-5Biodegradable Nanoparticles
  • Track 10-6Nano Dimensional Artificial Antigen Presenting Cells (aAPCs)

Genome editing with engineered nucleases (GEEN) is emergent type of genetic engineering. GEEN is the technology in which DNA is inserted, deleted or replaced in the genome. The emergence of highly versatile genome-editing technologies has provided investigators with the ability to rapidly and economically introduce sequence-specific modifications into the genomes of a broad spectrum of cell types and organisms. It also promotes various changes in sub cellular level. Genome editing itself also holds tremendous potential for treating the underlying various idiopathic genetic causes of certain diseases. The core technologies now most commonly used  techniques to facilitate genome editing are clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9),  transcription activator-like effector nucleases (TALENs), zinc-finger nucleases (ZFNs), and homing endonucleases or meganucleases.

  • Track 11-1Genetic Engineering
  • Track 11-2Zinc Finger Nucleases 
  • Track 11-3Crispr Technology
  • Track 11-4Talen Technology

Functionality of biomaterials for these forms is depends upon the chemical reaction such as localized or systemic response at the surface tethered moieties or encapsulated therapeutic factors such as drugs, genes, cells, growth factors, hormones and other active agents to specific target sites. The application of functional biomaterials is rehabilitation, reconstruction, regeneration, repair, ophthalmic applications and act as therapeutic solutions. It has the property of biocompatibility and produce inertness response to the tissue.   The biomaterial-mediated gene therapy aim to use polymeric gene therapy systems to halt the progression of neuron loss through neuroprotective routes and it combine stem cell therapy and biomaterials delivery system in order to enhance regeneration or repair after ischemic injury.

  • Track 12-1Homing Endonucleases or Meganucleases
  • Track 12-2Functional Biomaterial
  • Track 12-3Acquisition of Novel Biological or Molecular Diversity. 
  • Track 12-4DNA Synthesis
  • Track 12-5DNA Shuffling
  • Track 12-6Directed Design

Genetics in Health and Disease in which therapy utilizes genetics, imaging and biological indicators to understand predisposition to disease, what constitutes health during childhood and throughout the life course. Gene and Protein Function are used to develop tools, skills and resources to elucidate gene function and to inform development of new therapies using state-of the-art technologies. Personalised Medicine and Patient benefit is considered to ensure basic science discoveries of disease mechanisms and patient’s genomes are used to produce best effect to improve patients’ lives which include better diagnostics, identification of biomarkers and targeting of therapies.

  • Track 13-1Bioprospecting
  • Track 13-2Genotype-Specific Medicine
  • Track 13-3Phenotype-Specific Medicine
  • Track 13-4Epidermal Growth Factor Receptor (EGFR)
  • Track 13-5EGFR Inhibitor
  • Track 13-6Single Nucleotide Polymorphisms

The global market for cell and gene based therapies is expected to surpass the $20 billion USD mark by 2025, with an annual growth rate of 21%. The main targets for cell – based therapies are high impact disease areas with significant incurable needs, including cancer, heart disease, neurodegenerative diseases, musculoskeletal disorders and autoimmune diseases. Gene therapies should then not be rushed to market but companies should gather the required data about the impact of therapy in human community with the appropriate duration of follow-up to allow proper evaluation by payers. In addition, it is key to think about potential reimbursement of the techniques and also the pricing strategies, including risk sharing, as soon as the early clinical development phase.

  • Track 14-1Systems Biology
  • Track 14-2Computational Biology and Bioinformatics
  • Track 14-3DNA Computer
  • Track 14-4Annual Growth Rate
  • Track 14-5Commercial Collaboration

The enormous number of companies involved in cell therapy has increased progression remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 305 of these are profiled 291 alliances. Of these companies, 170 are involved in stem cells. The Profiles of 72 academic institutions in the US involved in cell therapy along with their commercial collaborations. Allogeneic technology with more than 350 clinical trials is poised to dominate the commercialization of cell therapies in market. Further R&D in cell and gene therapy is expected to bloom given the biologically based advantages.

  • Track 15-1Cell Therapy in Market
  • Track 15-2Allogenic Technology in Market
  • Track 15-3Cell and Gene Therapy Companies
  • Track 15-4Alliance Companies
  • Track 15-5Blooming Era of Gene Therapy